Skip to content

Abivax

  • About Us
    • Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Overview
    • Publications
  • Pipeline
    • Overview
    • Patients
    • Obefazimod for UC
    • Obefazimod for Crohn’s
    • Obefazimod for RA
    • ABX196 for HCC
  • News & Events
    • Press Releases
    • Press Coverage
    • Upcoming Events
  • Investors
    • Overview
    • Share Price
    • Investor Documents
    • General Meeting
  • Contact Us
  • ECCO 2022
Search
  • EN
  • FR
  • DE

News & Events

Press Coverage

  • 2022
  • 2021
  • 2020
  • 2019
  • 2018

Healio Gastroenterology

September 12, 2022

Obefazimod bests placebo, improves ulcerative colitis in phase 2b induction trial

Les Echos investir

September 7, 2022

Abivax publie les résultats de l’étude de phase 2b d’obefazimod (ABX464) dans la rectocolite hémorragique

La Gazette du Laboratoire

September 7, 2022

Abivax publie les résultats de l’étude de phase 2b d’obefazimod (ABX464) dans la rectocolite hémorragique

MedPage Today

September 7, 2022

First-in-Class Drug Brings Relief in Ulcerative Colitis

La Tribune Bourse

September 6, 2022

Abivax: une publication dans ‘The Lancet’ bien accueillie

  • 1
  • 2
  • 3
© 2023 All rights reserved by ABIVAX | Website created by Stratégie et communication digitale : JLL CONSEIL Privacy and Terms of Use
  • About Us
    • Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Overview
    • Publications
  • Pipeline
    • Obefazimod for UC
    • ABX196 for HCC
  • News & Events
    • Press Releases
    • Press Coverage
    • Upcoming Events
  • Investors
    • Share Profile
    • Share Price
    • Investor Documents
    • Analysts
    • General Meeting
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn
  • Follow us on YouTube
  • Follow us on Google+